Latest Healthcare It News

Healius Limited has announced a fully franked special dividend of 41.3 cents per share totaling approximately $300 million, alongside a new $300 million three-year syndicated bank facility replacing its previous $680 million arrangement.

Enlitic has signed a binding MoU with GE HealthCare to deliver up to A$50 million in migration services over five years, contingent on a A$10 million equity raise that the company has now initiated.

Kinatico (ASX:KYP) has upgraded its SaaS revenue forecast for the second half of FY25 to $8.3 million, driven by strong demand for its compliance and credential validation software. The company’s recent sales hires and April launch of Kinatico Compliance underpin this optimistic outlook.

Proteomics International Laboratories Ltd is raising up to $5.5 million through a $4 million placement and a $1 million Share Purchase Plan at $0.37 per share, offering shareholders a discounted entry and free attaching options.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

4DMedical has landed a significant commercial contract with Intermountain Health to deploy its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product, marking a key milestone in its U.S. expansion through a strategic Microsoft-backed partnership.

Enlitic, Inc. has launched a two-tranche institutional placement to raise A$10 million, underpinning its strategic collaboration with GE HealthCare and fueling expansion in AI-enabled medical imaging data migration.

Enlitic has formalised a binding MOU with GE HealthCare to deliver multi-million-dollar migration services, contingent on raising A$10 million through a new capital placement. This partnership and funding round mark a pivotal step in Enlitic’s growth strategy within AI-driven medical imaging.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.

Next Science Limited has successfully had a derivative complaint dismissed in Florida, while continuing legal action against former employees for breach of post-employment restraints.

Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.

MedAdvisor Limited’s trading suspension has been lifted immediately following the release of an announcement about the outcome of a court application under the Corporations Act 2001.